Markus Perl
Overview
Explore the profile of Markus Perl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heidenreich S, Egger-Heidrich K, Halter J, Jost L, Stolzel F, Perl M, et al.
Bone Marrow Transplant
. 2025 Jan;
PMID: 39809902
Belumosudil is a first in class ROCK2-inhibitor approved by the FDA for the 3rd line treatment of chronic graft-versus-host disease (cGvHD). In this retrospective real-world analysis, we report safety and...
2.
Staudt S, Nikolka F, Perl M, Franz J, Leblay N, Leblay N, et al.
bioRxiv
. 2024 Sep;
PMID: 39314273
The microbiome is a complex host factor and key determinant of the outcome of antibody-based and cellular immunotherapy. Its postbiotics are a blend of soluble commensal byproducts that are released...
3.
Knoedler L, Huelsboemer L, Hollmann K, Alfertshofer M, Herfeld K, Hosseini H, et al.
Front Immunol
. 2024 May;
15():1276306.
PMID: 38715609
Malignancies represent a persisting worldwide health burden. Tumor treatment is commonly based on surgical and/or non-surgical therapies. In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and...
4.
Perl M, Herfeld K, Harrer D, Hopting M, Schweiger M, Sterz U, et al.
Haematologica
. 2024 Mar;
109(9):2969-2977.
PMID: 38546698
Chimeric antigen receptor (CAR) T-cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that has up to now been considered the result...
5.
Doering J, Perl M, Weber D, Banas B, Schulz C, Hamer O, et al.
Transplant Cell Ther
. 2023 Sep;
29(12):772.e1-772.e10.
PMID: 37777112
Chronic graft-versus-host disease (cGVHD) is the leading cause of late nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (alloHSCT) and defined by 8 diagnostic target organs. Recently, provisional criteria...
6.
Heidegger S, Stritzke F, Dahl S, Dassler-Plenker J, Joachim L, Buschmann D, et al.
Cell Rep Med
. 2023 Sep;
4(9):101171.
PMID: 37657445
Tumor-derived extracellular vesicles (EVs) have been associated with immune evasion and tumor progression. We show that the RNA-sensing receptor RIG-I within tumor cells governs biogenesis and immunomodulatory function of EVs....
7.
Knoedler L, Oezdemir B, Moog P, Prantl L, Broer P, Knoedler C, et al.
Aesthetic Plast Surg
. 2022 Aug;
47(1):490-497.
PMID: 35922668
Plastic surgeons are trained to perform a wide repertoire of surgeries-ranging from standard local procedures to highly specialized operations. Therefore, plastic surgeons treat a plethora of clinical presentations and address...
8.
Ehrenfeld M, Schrade A, Flisikowska T, Perl M, Hirsch N, Sichler A, et al.
Mol Cancer Ther
. 2022 Jan;
21(4):686-699.
PMID: 35086950
The B subunit of bacterial Shiga toxin (STxB) is nontoxic and has low immunogenicity. Its receptor, the glycosphingolipid Gb3/CD77, is overexpressed on the cell surface of human colorectal cancer. We...
9.
Ecker J, Benedetti E, Kindt A, Horing M, Perl M, Machmuller A, et al.
Gastroenterology
. 2021 May;
161(3):910-923.e19.
PMID: 34000281
Objective: Lipidomic changes were causally linked to metabolic diseases, but the scenario for colorectal cancer (CRC) is less clear. We investigated the CRC lipidome for putative tumor-specific alterations through analysis...
10.
Authier D, Hegenbart U, Pohl F, Rosenwald A, Kircher S, Menhart K, et al.
Leuk Lymphoma
. 2021 Mar;
62(9):2267-2271.
PMID: 33787427
No abstract available.